A Phase Ib Trial of Concurrent Cetuximab (ERBITUX) and Intensity Modulated Radiotherapy (IMRT) With Ipilimumab (YERVOY) in Locally Advanced Head and Neck Cancer
Latest Information Update: 19 Jun 2023
Price :
$35 *
At a glance
- Drugs Ipilimumab (Primary) ; Cetuximab
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- 28 Jan 2022 Results assessing the tolerability and yields acceptable survival without cytotoxic chemotherapy, published in the Clinical Cancer Research.
- 28 Sep 2019 Results (n=18) evaluating the plasma-derived exosomes as bio-markers of response to immunotherapy in patients with head and neck squamous cell carcinoma patients presented at the 5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference
- 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress